Literature DB >> 22674548

FOXP3 expression in tumor cells and implications for cancer progression.

Tiziana Triulzi1, Elda Tagliabue, Andrea Balsari, Patrizia Casalini.   

Abstract

FOXP3 is a member of the forkhead/winged-helix family of transcriptional regulators. Defects in the FOXP3 gene cause an X-linked autoimmune/immunodeficiency syndrome in humans and the Scurfy phenotype in mice. FOXP3 acts mainly in regulating the development and function of CD4+CD25+ regulatory T cells. Although initially thought to be specific for these cells, FOXP3 expression has recently been described in non-hematopoietic cells, including epithelial cells of multiple lineages and of different tissue origins. Moreover, FOXP3 expression has been detected in tumor cells of both epithelial and non-epithelial tissues. The role of FOXP3 expression by tumor cells remains controversial, with in vitro studies pointing to an onco-suppressive action, whereas studies conducted on human samples associate FOXP3 expression by tumor cells with metastatic spread. Here, we review evidence for the multi-faceted role of FOXP3 in cancer cells.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22674548     DOI: 10.1002/jcp.24125

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  34 in total

1.  IPEX Syndrome, FOXP3 and Cancer.

Authors:  Runhua Liu; Silin Li; Wei-Hsiung Yang; Lizhong Wang
Journal:  J Syndr       Date:  2013-06

Review 2.  From cell biology to immunology: Controlling metastatic progression of cancer via microRNA regulatory networks.

Authors:  Jae Hyon Park; Evropi Theodoratou; George A Calin; Jae Il Shin
Journal:  Oncoimmunology       Date:  2016-09-09       Impact factor: 8.110

3.  Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma.

Authors:  Leiguang Ye; Songlei Guan; Cong Zhang; Kuang-Hui Lee; Shilong Sun; Jun Wei; Baogang Liu
Journal:  Tumour Biol       Date:  2013-03-13

4.  Overexpression of the transcription factor FOXP3 in lung adenocarcinoma sustains malignant character by promoting G1/S transition gene CCND1.

Authors:  Yinan Li; Dong Li; Wei Yang; Haiying Fu; Yaqing Liu; Yi Li
Journal:  Tumour Biol       Date:  2015-12-16

5.  Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types.

Authors:  Mayanne M T Zhu; Samantha Burugu; Dongxia Gao; Jamie Yu; Zuzana Kos; Samuel Leung; Basil A Horst; Torsten O Nielsen
Journal:  Mod Pathol       Date:  2020-04-29       Impact factor: 7.842

6.  The Prognostic Value of Forkhead Box P3 Expression in Operable Breast Cancer: A Large-Scale Meta-Analysis.

Authors:  Shu Chen Lin; Zhi Hua Gan; Yang Yao; Da Liu Min
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

7.  Premature expression of Foxp3 in double-negative thymocytes.

Authors:  Melanie M Barra; David M Richards; Ann-Cathrin Hofer; Michael Delacher; Markus Feuerer
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

8.  FOXP3 facilitates the invasion and metastasis of non-small cell lung cancer cells through regulating VEGF, EMT and the Notch1/Hes1 pathway.

Authors:  Chun Li; Hefei Wang; Hui Fang; Chengyuan He; Yijie Pei; Xiaodong Gai
Journal:  Exp Ther Med       Date:  2021-07-06       Impact factor: 2.447

Review 9.  Transcription factor interplay in T helper cell differentiation.

Authors:  Catherine M Evans; Richard G Jenner
Journal:  Brief Funct Genomics       Date:  2013-07-22       Impact factor: 4.241

10.  FOXP3 transcription factor: a candidate marker for susceptibility and prognosis in triple negative breast cancer.

Authors:  Leandra Fiori Lopes; Roberta Losi Guembarovski; Alda Losi Guembarovski; Marina Okuyama Kishima; Clodoaldo Zago Campos; Julie Massayo Maeda Oda; Carolina Batista Ariza; Karen Brajão de Oliveira; Sueli Donizete Borelli; Maria Angelica Ehara Watanabe
Journal:  Biomed Res Int       Date:  2014-04-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.